Abstract
Quantitative outcome variables in Alzheimer’s disease (AD) are of interest because of their low longitudinal variability compared with that of repeated clinical and cognitive measurements. Conventional MR-based volumetry of structures within and beyond the medial temporal lobe has proven to be useful in the diagnostic work up of early AD patients, and measures of atrophy have the potential to monitor the efficacy of disease-modifying agents. The extensive application of new non-conventional MR-based techniques to the study of AD, such as proton magnetic resonance spectroscopy, diffusion tensor MRI, and functional MRI, has undoubtedly improved our understanding of the pathophysiology of the disease, and might lead to the identification of additional useful markers of disease progression. This review summarizes the main results obtained from the application of conventional and non-conventional MRI in AD patients, and supports their more extensive use in studies of disease evolution and clinical trials.
Keywords: Alzheimer’s disease, magnetic resonance imaging (MRI), medial temporal lobe (MTL) atrophy, voxel-based morphometry, proton magnetic resonance spectroscopy (1H-MRS), diffusion tensor MRI (DT MRI), functional MRI (fMRI), resting state fMRI, MTL atrophy
Current Alzheimer Research
Title:Magnetic Resonance Imaging in Alzheimer’s Disease: from Diagnosis to Monitoring Treatment Effect
Volume: 9 Issue: 10
Author(s): M. Filippi, F. Agosta, G.B. Frisoni, N. De Stefano, A. Bizzi, M. Bozzali, A. Falini, M.A. Rocca, S. Sorbi, C. Caltagirone and G. Tedeschi
Affiliation:
Keywords: Alzheimer’s disease, magnetic resonance imaging (MRI), medial temporal lobe (MTL) atrophy, voxel-based morphometry, proton magnetic resonance spectroscopy (1H-MRS), diffusion tensor MRI (DT MRI), functional MRI (fMRI), resting state fMRI, MTL atrophy
Abstract: Quantitative outcome variables in Alzheimer’s disease (AD) are of interest because of their low longitudinal variability compared with that of repeated clinical and cognitive measurements. Conventional MR-based volumetry of structures within and beyond the medial temporal lobe has proven to be useful in the diagnostic work up of early AD patients, and measures of atrophy have the potential to monitor the efficacy of disease-modifying agents. The extensive application of new non-conventional MR-based techniques to the study of AD, such as proton magnetic resonance spectroscopy, diffusion tensor MRI, and functional MRI, has undoubtedly improved our understanding of the pathophysiology of the disease, and might lead to the identification of additional useful markers of disease progression. This review summarizes the main results obtained from the application of conventional and non-conventional MRI in AD patients, and supports their more extensive use in studies of disease evolution and clinical trials.
Export Options
About this article
Cite this article as:
Filippi M., Agosta F., Frisoni G.B., De Stefano N., Bizzi A., Bozzali M., Falini A., Rocca M.A., Sorbi S., Caltagirone C. and Tedeschi G., Magnetic Resonance Imaging in Alzheimer’s Disease: from Diagnosis to Monitoring Treatment Effect, Current Alzheimer Research 2012; 9 (10) . https://dx.doi.org/10.2174/156720512804142949
DOI https://dx.doi.org/10.2174/156720512804142949 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunotherapy for Alzheimers Disease: Potential Problems and Possible Solutions
Current Immunology Reviews (Discontinued) Challenges in Chagas Disease Drug Discovery: A Review
Current Medicinal Chemistry Anti-Viral Agents in Neurodegenerative Disorders: New Paradigm for Targeting Alzheimer’s Disease
Recent Patents on Anti-Infective Drug Discovery Blood-Brain Barrier Alterations in MDX Mouse, An Animal Model of the Duchenne Muscular Dystrophy
Current Neurovascular Research COVID-19, the Brain, and the Future: Is Infection by the Novel Coronavirus a Harbinger of Neurodegeneration?
CNS & Neurological Disorders - Drug Targets HTLV-1 Associated Neurological Disorders
Current Topics in Medicinal Chemistry Global Warming Favors Pathogenicity of the Brain-Eating Amoebae
Anti-Infective Agents In Vivo DNA Electrotransfer for Immunotherapy of Cancer and Neurodegenerative Diseases
Current Drug Metabolism APP Transgenic Mouse Models and their Use in Drug Discovery to Evaluate Amyloid-β Lowering Therapeutics
CNS & Neurological Disorders - Drug Targets Inactivation of Pathogenic Microorganisms by Photodynamic Techniques:Mechanistic Aspects and Perspective Applications.
Anti-Infective Agents in Medicinal Chemistry Brain-eating Amoebae Infection: Challenges and Opportunities in Chemotherapy
Mini-Reviews in Medicinal Chemistry Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research Parasite Prolyl Oligopeptidases and the Challenge of Designing Chemotherapeuticals for Chagas Disease, Leishmaniasis and African Trypanosomiasis
Current Medicinal Chemistry Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS
Current Pharmaceutical Design Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Intravenous Immunoglobulins for Alzheimer's Disease
Current Alzheimer Research Ginkgo Biloba Extract (EGb 761) in Alzheimers Disease: Is there Any Evidence?
Current Alzheimer Research Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets